DESCRIPTION: The increased risk of endometrial cancer associated with the
use of postmenopausal estrogen therapy can be diminished by the concomitant
use of progestogen on a cyclic basis. Nevertheless, it is quite uncertain
whether the entirety of the increased risk is eliminated, especially in
long-term users of cyclic estrogen/progestogen regimens. Additionally, the
impact on endometrial cancer incidence of a now-common way of taking
hormones, on a combined-continuous basis, has never been evaluated. To
address these questions, a population-based case-control study of
endometrial cancer is proposed for women 50-60 years of age who reside in
three counties of western Washington. An attempt will be made to interview
eligible cases diagnosed during 1997-1999 regarding the use of hormonal
medications and other exposures and characteristics that bear on the
incidence of endometrial cancer. As a basis of comparison for the cases who
are 50-64 years of age, interviews will be sough with 50-64 year-old female
residents of these counties identified through random digit dialing.
Controls 65-69 years of age will be identified through the records of the
Health Care Financing Administration, and they will be interviewed as well.
Potential controls who have previously had a hysterectomy will be excluded.
We anticipate obtaining interviews with approximately 300 cases and an equal
number of controls. Exogenous hormones offer postmenopausal women
substantial benefits with regard to their cardiovascular and skeletal
systems. The proposed study has the potential to obtain information that
can guide their choice of hormonal regimen so as to minimize the likelihood
of endometrial cancer as an adverse effect of this otherwise useful therapy.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.